Evidence map›Paper›PMID 20600241›Full record

ReviewFrontiers in neuroendocrinology2010

Leptin in human physiology and therapeutics.

Tina A Dardeno, Sharon H Chou, Hyun-Seuk Moon, John P Chamberland, Christina G Fiorenza, Christos S Mantzoros

Open access · bronzeAbstract readReview
In one paragraph

Review in Frontiers in neuroendocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 4 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 4 syntheses or guidelines pooled it, 286 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Leptin Aggravates Thoracic Aortic Dissection Through Impairment of Energy Metabolism in Nrip2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  16. Article
  17. Identification of serum biomarkers associated with microvascular functions in a long-term high-fat diet-induced obesity rat model.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  18. Review
  19. Childhood Obesity: Insight into Kidney Involvement.International journal of molecular sciences · 2023
    Review
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tina A DardenoDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States.
Sharon H Chou
Hyun-Seuk Moon
John P Chamberland
Christina G Fiorenza
Christos S Mantzoros
Beth Israel Deaconess Medical Center · USHarvard University · US

Funding

Role of Leptin in the Neuroendocrine Response to FastingR01DK058785 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MANTZOROS, CHRISTOS S · 2001 to 2011
$4.0M
The Role of Leptin in the Maintenance of a Reduced Body WeightR01DK079929 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MANTZOROS, CHRISTOS S · 2008 to 2012
$1.8M
Leptin and Adipokine PhysiologyK24DK081913 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MANTZOROS, CHRISTOS S · 2008 to 2020
$1.5M
Role of Leptin in the Neuroendocrine Response to FastingR56DK058785 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MANTZOROS, CHRISTOS S · 2005 to 2005
$85k
NIDDK NIH HHS DK079929NIDDK NIH HHS DK081913NIDDK NIH HHS DK58785NIDDK NIH HHS K24 DK081913NIDDK NIH HHS R01 DK058785NIDDK NIH HHS R01 DK079929NIDDK NIH HHS R56 DK058785
6 · The paper itself

Abstract

Leptin regulates energy homeostasis and reproductive, neuroendocrine, immune, and metabolic functions. In this review, we describe the role of leptin in human physiology and review evidence from recent "proof of concept" clinical trials using recombinant human leptin in subjects with congenital leptin deficiency, hypoleptinemia associated with energy-deficient states, and hyperleptinemia associated with garden-variety obesity. Since most obese individuals are largely leptin-tolerant or -resistant, therapeutic uses of leptin are currently limited to patients with complete or partial leptin deficiency, including hypothalamic amenorrhea and lipoatrophy. Leptin administration in these energy-deficient states may help restore associated neuroendocrine, metabolic, and immune function and bone metabolism. Leptin treatment is currently available for individuals with congenital leptin deficiency and congenital lipoatrophy. The long-term efficacy and safety of leptin treatment in hypothalamic amenorrhea and acquired lipoatrophy are currently under investigation. Whether combination therapy with leptin and potential leptin sensitizers will prove effective in the treatment of garden-variety obesity and whether leptin may have a role in weight loss maintenance is being greatly anticipated.

Indexed as

Energy MetabolismHomeostasisHumansImmune SystemLeptinMetabolic DiseasesModels, BiologicalNeurosecretory SystemsObesityReproductionSignal TransductionLeptin

Identifiers

PMID20600241
PMCPMC2916735
OpenAlexW2015130768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.